Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1

• Main Authors: Carlo Giaquinto, Muthuhadini Patience Mawela, Kulkanya Chokephaibulkit, Marinella Della Negra, Ismail Haroon Mitha, Jan Fourie, Annie Fang, Elna van der Ryst, Srinivas Rao Valluri, Manoli Vourvahis, Rebecca Yanhui Zhang-Roper, Charles Craig, Lynn McFadyen, Andrew Clark, Jayvant Heera
• Other Authors: ViiV Healthcare
• Format: Article
• Published: 2019
• Subjects: Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/46736
• Institution: Mahidol University

BACKGROUND: Maraviroc is a CC-chemokine receptor 5 antagonist approved to treat adults infected with CC-chemokine receptor 5-tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the pharmacokinetics, safety and efficacy of maraviroc in combination with optimized background therapy in treatmen...